Global Intravitreal Injectable Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Intravitreal Injectable market size will reach US$ 28490 million by 2031.
Intravitreal injectables are sterile pharmaceutical formulations administered directly into the vitreous humor of the eye using a fine needle. This route of administration allows for targeted delivery of medications—such as anti-VEGF agents, corticosteroids, or antibiotics—into the posterior segment of the eye, ensuring high local drug concentrations while minimizing systemic exposure. Intravitreal injections are commonly used to treat retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and infectious endophthalmitis.
The global intravitreal injectable market has experienced steady growth in recent years, driven primarily by the rising prevalence of retinal disorders such as macular edema, age-related macular degeneration (AMD), and retinal vein occlusion (RVO). Leading pharmaceutical players in this space include Regeneron Pharmaceuticals (notably with Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, and Kanghong Pharmaceutical. These top five companies collectively account for over 70% of global market share, reflecting a relatively concentrated competitive landscape. North America currently dominates the global market, holding a share of more than 50%, followed by Europe and Asia-Pacific, each with shares exceeding 40%.
In terms of drug types, anti-VEGF (vascular endothelial growth factor) therapies represent the largest and most significant market segment, contributing to over 85% of total market revenue. These agents are highly effective in inhibiting abnormal blood vessel growth in the retina, making them the standard of care for diseases like AMD and diabetic macular edema (DME). Other therapeutic classes such as corticosteroids and antibiotics play smaller roles, typically in more specialized or adjunctive treatment scenarios.
The largest clinical application of intravitreal injectables is for macular edema, which continues to see a rise in incidence linked to diabetes and aging populations worldwide. Macular degeneration and RVO are also major contributors to demand, reinforcing the importance of targeted ophthalmic treatments. The increase in awareness, earlier diagnosis, and improved accessibility to eye care services are further driving market expansion across both developed and emerging regions.
Looking ahead, the market is expected to grow steadily due to increasing disease burden and product innovation. Notably, new players such as Astellas Pharma have begun entering the market, signaling a shift toward broader competition and possibly next-generation therapies with extended efficacy and dosing intervals. Advances in drug delivery systems, longer-acting formulations, and biosimilars are expected to further shape the landscape and offer new growth opportunities.
LPI (LP Information)' newest research report, the “Intravitreal Injectable Industry Forecast” looks at past sales and reviews total world Intravitreal Injectable sales in 2024, providing a comprehensive analysis by region and market sector of projected Intravitreal Injectable sales for 2025 through 2031. With Intravitreal Injectable sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injectable industry.
This Insight Report provides a comprehensive analysis of the global Intravitreal Injectable landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Intravitreal Injectable portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravitreal Injectable market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injectable and breaks down the forecast by Drug, by Disease, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injectable.
This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injectable market by product type, application, key players and key regions and countries.
Segmentation by Drug:
Anti-VEGF
Steroids
Others
Segmentation by Disease:
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals (Eylea)
Allergan
EyePoint Pharmaceuticals
Genentech
Kanghong Pharmaceutical
Astellas Pharma
Clearside Biomedical
Bayer
Please note: The report will take approximately 2 business days to prepare and deliver.
Intravitreal injectables are sterile pharmaceutical formulations administered directly into the vitreous humor of the eye using a fine needle. This route of administration allows for targeted delivery of medications—such as anti-VEGF agents, corticosteroids, or antibiotics—into the posterior segment of the eye, ensuring high local drug concentrations while minimizing systemic exposure. Intravitreal injections are commonly used to treat retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and infectious endophthalmitis.
The global intravitreal injectable market has experienced steady growth in recent years, driven primarily by the rising prevalence of retinal disorders such as macular edema, age-related macular degeneration (AMD), and retinal vein occlusion (RVO). Leading pharmaceutical players in this space include Regeneron Pharmaceuticals (notably with Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, and Kanghong Pharmaceutical. These top five companies collectively account for over 70% of global market share, reflecting a relatively concentrated competitive landscape. North America currently dominates the global market, holding a share of more than 50%, followed by Europe and Asia-Pacific, each with shares exceeding 40%.
In terms of drug types, anti-VEGF (vascular endothelial growth factor) therapies represent the largest and most significant market segment, contributing to over 85% of total market revenue. These agents are highly effective in inhibiting abnormal blood vessel growth in the retina, making them the standard of care for diseases like AMD and diabetic macular edema (DME). Other therapeutic classes such as corticosteroids and antibiotics play smaller roles, typically in more specialized or adjunctive treatment scenarios.
The largest clinical application of intravitreal injectables is for macular edema, which continues to see a rise in incidence linked to diabetes and aging populations worldwide. Macular degeneration and RVO are also major contributors to demand, reinforcing the importance of targeted ophthalmic treatments. The increase in awareness, earlier diagnosis, and improved accessibility to eye care services are further driving market expansion across both developed and emerging regions.
Looking ahead, the market is expected to grow steadily due to increasing disease burden and product innovation. Notably, new players such as Astellas Pharma have begun entering the market, signaling a shift toward broader competition and possibly next-generation therapies with extended efficacy and dosing intervals. Advances in drug delivery systems, longer-acting formulations, and biosimilars are expected to further shape the landscape and offer new growth opportunities.
LPI (LP Information)' newest research report, the “Intravitreal Injectable Industry Forecast” looks at past sales and reviews total world Intravitreal Injectable sales in 2024, providing a comprehensive analysis by region and market sector of projected Intravitreal Injectable sales for 2025 through 2031. With Intravitreal Injectable sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intravitreal Injectable industry.
This Insight Report provides a comprehensive analysis of the global Intravitreal Injectable landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Intravitreal Injectable portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Intravitreal Injectable market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intravitreal Injectable and breaks down the forecast by Drug, by Disease, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intravitreal Injectable.
This report presents a comprehensive overview, market shares, and growth opportunities of Intravitreal Injectable market by product type, application, key players and key regions and countries.
Segmentation by Drug:
Anti-VEGF
Steroids
Others
Segmentation by Disease:
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals (Eylea)
Allergan
EyePoint Pharmaceuticals
Genentech
Kanghong Pharmaceutical
Astellas Pharma
Clearside Biomedical
Bayer
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
94 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
